May 2019 CPN

CPN

Community Pharmacy News – May 2019

Community pharmacy: 2019 and beyond

PSNC animation describes how community pharmacies will fit into the NHS of the future CEO Blog | CPCF screening survey | Price change mechanism factsheet

PSNC’S WORK

FUNDING AND STATISTICS

CONTRACT AND IT

Chief Executive’s blog PSNC Chief Executive Simon Dukes uses this section of CPN to provide an update on PSNC’s work. prevention and reducing pressure on urgent care; NHS England wants to expand the Digital Minor Illness Referral Service (DMIRS); and PSNC is pressing for a multi-year contract to provide stability during a period of primary care transformation.

Simon Dukes

PSNC Chief Executive This month marks a year since I became Chief Executive at PSNC. When I first arrived, community pharmacy and the Department of Health and Social Care (DHSC) were coming to the end of a bruising Judicial Review. We have come a long way since then, and in April we embarked upon the first set of community pharmacy contract negotiations for five years.

I must admit that I didn’t expect it to take quite this long to start negotiations with DHSC and NHS England, following the launch of the NHS Long Term Plan and GP Contract, we now have a clearer picture of what our customer wants and we are ready to make the most of this opportunity.

“

PSNC is pressing for a multi-year contract to provide stability during a period of primary care transformation

”

All three parties have given an indication of their top priorities for these negotiations: DHSC is interested in the role community pharmacy can play in

2 Community Pharmacy News – May 2019

One of the biggest challenges we face in the negotiations is the need to consider how any proposals could be adopted across a variety of different business models. And whilst our negotiating team representing independent, small chain and large multiples are wrestling with that, contractors on the ground need to prepare themselves for the inevitable changes required to meet the Government’s future plans for healthcare.

Community pharmacy will eventually be doing more to provide services that help people to stay healthy.

We recommend that all pharmacy contractors start reviewing their current procedures and identifying ways to free up capacity, such as: • Making better use of technology and other team members’ skills; • Finding ways to interact with patients digitally; and • Updating your skills to provide the services the NHS needs.

Moreover, with the development of Primary Care Networks (PCNs) due to encompass a range of community healthcare professionals, contractors will need to learn how to engage and work effectively alongside not only GP practices, but also their neighbouring pharmacies.

On average, around 10 community

“

PSNC will be with you every step of the way

”

pharmacies will sit in each PCN footprint, and these pharmacies will need to work together to engage with their PCN. Your LPC can help with advice and guidance on how to do this.

To get the ball rolling, have a look at the first in a series of our animations on the future of pharmacy and use the accompanying resources list to start thinking about what you need to do next (see psnc.org.uk/futureofpharmacy). You may also find NHS England’s PCN series of webinars helpful. These will focus on a range of topics, including the role of pharmacy, and will highlight examples of work already in progress across the country. Details of the webinars can be found here: ow.ly/ROCD30oOMXx LPCs and pharmacy teams will be instrumental in driving forward change for the sector, but please be assured that PSNC will be with you every step of the way. As well as working to get the best possible deal for community pharmacy in the negotiations, my team and I will continue to work with the other national pharmacy organisations to provide guidance and resources for both contractors and LPCs to help them to cement community pharmacy’s place in the future of the NHS. Look out for more on PCNs coming soon to the website: psnc.org.uk/pcnresources

Make sure you get all the latest Community Pharmacy News delivered to your inbox, by signing up at psnc.org.uk/email

DISPENSING AND SUPPLY

SERVICES AND COMMISSIONING

THE HEALTHCARE LANDSCAPE

LPCS

Future of pharmacy animation is launched Pharmacy is changing: PSNC’s video animation aims to help community pharmacy teams to start to prepare for their future role in the NHS PSNC has launched a video animation explaining how community pharmacies are likely to fit into the NHS of the future.

PSNC and the other national community pharmacy representative bodies.

As well as showcasing the work that pharmacies already do, the video describes the transformation that community pharmacies will need to undertake over the coming months and years.

PSNC is in contact with NHS England and GP representatives to highlight the role that community pharmacies can play in PCNs. National messaging to GPs will encourage them to ensure that pharmacies are kept in the loop once PCNs are formed.

PSNC has based the video on the ambitions for community pharmacy that have been set out by NHS England and the Government; we are continuing to work closely with AIM, CCA, NPA and the RPS as well as the LPCs to influence these plans and to find ways to make them work for the sector.

The Government has made clear through the NHS Long Term Plan and GP Contract that it wants to better utilise the skills and reach of community pharmacy. However, this will require the sector to embrace a series of changes which we must start planning for now.

In particular, the emergence of Primary Care Networks (PCNs) – which must be formed by July 2019 – will bring changes for all healthcare providers working in the community, and it will be up to everyone in community pharmacy to ensure that our sector is included in these important emerging structures. Contractors and LPCs will need to be proactive in talking to one another to coordinate engagement with local GPs and PCNs, supported by

Our animation gives community pharmacies four action points to consider: 1. Start a conversation with other local pharmacies about how to collaborate within PCNs; 2. Together with other pharmacies and your LPC, talk to local GPs about their plans for the future; 3. Take all opportunities for further training and to provide services; and 4. Make contact with your LPC. PSNC has created a resources list to help contractors to start working towards these points, and we will add to this as we develop new resources over the coming months. This is available from our animation webpage: psnc.org.uk/futureofpharmacy View PSNC’s animation and learn more about the future of pharmacy at: ow.ly/nDEY30ozJmr

PSNC in the media

PSNC CEO Simon Dukes provides an insight into pharmacy funding negotiations in a Chemist+Druggist blog: ow.ly/voA950uezaA

Support for the Future of Pharmacy Animation stretches beyond the English pharmacy sector Search #futureofpharmacy on Twitter

InPharmacy Magazine interviews Simon Dukes as he reaches one year as PSNC CEO: ow.ly/APuw30oMZZ8

psnc.org.uk 3

CONTRACT AND IT

Call to improve rural pharmaceutical services The House of Lords Select Committee on the Rural Economy recently published a report which has recommended that the Government takes steps to improve pharmaceutical services in rural areas.

PSNC, along with Community Pharmacy Wales, submitted evidence to the inquiry, advocating greater utilisation of community pharmacies to deliver healthcare needs for communities.

In particular, PSNC drew attention to the Essential Small Pharmacies Local Pharmaceutical Services (ESPLPS) scheme, which sustained rural pharmacies for many years until it ceased in March 2017. View the report in full at: ow.ly/Fg9v30oH9k0

Invitation to test market entry portal PSNC is liaising with Primary Care Support England (PCSE) on the development of its market-entry online portal, which will see the replacement of multiple paper forms with one single online application.

As part of this work, PCSE would now like to offer contractors a preview of the system, giving an opportunity to share any feedback and participate in testing. For further information, please contact the PCSE Pharmacy Engagement team on: pcse.pharmacyengagement@nhs.net

Are you faxing to the intended recipient?

NHS England has received reports of faxes inadvertently being sent by pharmacies to a hotel chain.

The hotel chain in question (fax number 0330 333 2812) has a similar fax number to the one for Alliance Healthcare’s prescription validation service (0330 332 8126). All pharmacies should check that their record of this Alliance fax number is correct.

Any breaches of information governance security should be reported so that the incident can be investigated and learning shared where necessary.

4 Community Pharmacy News – May 2019

DISPENSING AND SUPPLY

SERVICES AND COMMISSIONING

CPAF screening process to begin shortly The 2019/20 CPAF screening survey will be available for completion by community pharmacy contractors during the month of June.

“

Answering a short survey could mean your pharmacy avoids unnecessary monitoring visits

”

The 2019/20 Community Pharmacy Assurance Framework (CPAF) screening questionnaire will soon be made available for completion. It will be open between Monday 3rd June 2019 and Sunday 30th June 2019.

The process asks all NHS community pharmacy contractors to complete a short screening questionnaire consisting of 10 active questions which should be answered; NHS England will then select a small number of pharmacies for a monitoring visit and/or to complete the full CPAF questionnaire.

Level 2 is the minimum standard expected to demonstrate general compliance with the terms of service, but reports show that contractors often aim to attain Level 3.

Last year’s CPAF screening process was positive, with 98.2% of contractors responding to the questionnaire. Following analysis of contractor feedback from last year, PSNC and NHS England have agreed the following revisions: • new wording to the safeguarding question to make it possible for contractors to attain Level 3 without requiring a safeguarding issue to have occurred in their pharmacy; and • the pharmacy-based audit question relates specifically to contractors’ 2018/19 audit activity.

More information will be provided in PSNC guidance due to be released shortly. An updated PSNC briefing about completing the screening survey will not only fully explain these changes but also provide clarification on some of the questions asked. The guidance will be available from psnc.org.uk/CPAF in June.

The questionnaire may also be viewed in advance from the above link. However, please note this is in PDF format for reference only and cannot be submitted.

How to complete the screening survey Community pharmacies should receive information and instructions on how to complete the screening questionnaire via email. This may come from the NHS Business Services Authority (NHSBSA) or the pharmacy’s Head Office.

If you have not received details of the questionnaire by week commencing 27th May 2019, please contact NHSBSA via nhsbsa.cpaf@nhs.net

TH

HE HEALTHCARE LANDSCAPE

LPCS

PSNC’S WORK

FUNDING AND STATISTICS

Mandatory oral health campaign The NHS England children’s oral health campaign has been chosen as one of the compulsory six public health campaigns for community pharmacy in 2019/20.

The NHS England community pharmacy oral health campaign, which coincides with National Smile Month, is now well underway.

Community pharmacy contractors are required to participate in this campaign, which runs until 13th June 2019, because it is one of six campaigns agreed as part of the Community Pharmacy Contractual Framework.

All pharmacies were sent campaign materials via Colgate-Palmolive, including a large ‘Monster teeth’ poster as well as leaflets and brushing charts, which pharmacy teams may wish to give to people visiting the pharmacy.

Contractors are also free to use Public Health England (PHE)’s materials on this topic, for example ‘Top 3 interventions for preventing tooth decay’ and ‘A quick guide to a healthy mouth in children’.

A training assessment on children’s oral health was included in the last Quality Payments Scheme, so those pharmacy team members who undertook the relevant Centre for Pharmacy Postgraduate Education (CPPE) training should already be well versed in the campaign’s key messages.

If you have not already done so, please make sure that all patient-facing staff: 1. Read the campaign letter from NHS England and PHE’s A quick guide to a healthy mouth in children so they are ready to communicate this advice to appropriate visitors to the pharmacy; 2. Can identify likely opportunities to provide advice to families and carers of children under five years; and 3. Know where to signpost families and carers for local dental services.

For more information, please visit: psnc.org.uk/publichealth

NUMSAS: are you claiming correctly?

Following the extension of the NHS Urgent Medicine Supply Advanced Service (NUMSAS) pilot until September 30th 2019, community pharmacy contractors are reminded of the correct processes when claiming for quantities, submitting tokens, and dealing with requests for gabapentin and pregabalin.

Contractors may find PSNC Briefing 034/17 useful when claiming for payment as it contains a checklist for completing an FP10DT EPS dispensing token, and for submitting the tokens and monthly claim form. Learn more at: ow.ly/mxjr30oxbcl

BNF 77 distance learning programme

Learn how new recommendations and information in the BNF will affect your clinical practice in the Centre for Pharmacy Postgraduate Education (CPPE)’s new course.

We are delighted to announce that our What’s new in BNF 77? distance learning programme is now live on our website.

Sneha Varia Regional Manager, East of England, CPPE

This interactive programme accompanies the 77th edition of the British National Formulary (BNF), which was released in March 2019 and highlights the key changes through a series of case studies.

The programme contains ten case studies that help you keep up to date with significant changes in the BNF, and should take around one hour to complete. The aim of the programme is to help pharmacy professionals identify situations in the healthcare setting where the management of a patient is affected by these changes. The case studies cover topics such as diabetic neuropathy, cardiovascular risk prevention and Alzheimer’s dementia.

After completing the programme, participants will be able to locate information on the latest changes in the BNF and recommend appropriate courses of action based on knowledge of the patient and the new information in the BNF. As this programme is interactive, you will be able to type notes in the answer boxes and save your answers to the case studies by saving the PDF to your computer, or you have the option to print it out.

This programme, which is available to all CPPE registrants, can be accessed from: www.cppe.ac.uk/programmes/l/bnf77-p-01 The accompanying e-assessment, which will enable you to complete a CPD entry on the learning towards your revalidation, can be found at: www.cppe.ac.uk/programmes/l/bnf77-a-01

psnc.org.uk 5

DISPENSING AND SUPPLY

SERVICES AND COMMISSIONING

THE HEALTHCARE LANDSCAPE

PSNC webinar: Understanding your Schedule of Payments The latest PSNC and NHSBSA webinar will describe how your pharmacy’s Schedule of Payments is compiled and teach you how to use it to monitor performance.

PSNC and the NHS Business Services Authority (NHSBSA) will be holding a Schedule of Payments webinar on Tuesday 11th June at 7.30pm.

The webinar will aim to help community pharmacy contractors to better understand their FP34 Schedule of Payments.

During the online event PSNC and NHSBSA will: • Explain how your pharmacy’s monthly Schedule of Payments is put together; • Highlight how potential discrepancies between the FP34c and FP34 can creep in; • Describe where to find various fees and payments in the Schedule; • Illustrate why your monthly payments may fluctuate; and • Show you how to use your Schedule to monitor performance.

During the 60-minute webinar viewers will also be given the opportunity to ask questions.

So, if you want to better understand the payments your pharmacy receives from the NHS, please join us for the ‘Understanding your Schedule of Payments’ webinar.

Book your place now: psnc.org.uk/webinar Even if you are unable to attend the webinar live, it is still worth registering for the event so that you will be sent a link to the recorded version of the webinar as soon as it becomes available.

Experiencing supply issues?

Pharmacy teams who experience problems in obtaining medicines (generic or branded) or appliances are reminded to feed this back to the PSNC Dispensing and Supply Team to support our ongoing representation of issues in the supply chain.

PSNC reports the feedback received to the Department of Health and Social Care to support their monitoring of the situation. It is also used in discussions with manufacturers, for example, highlighting problems with contingency arrangements.

Please make sure you let us know about any supply issues by using our online feedback forms at: psnc.org.uk/feedback

Can it be dispensed on an FP10?

When pharmacy teams receive NHS prescriptions, they must check whether the items prescribed are allowed on the NHS before dispensing otherwise the contractor may not be paid for them. Below are some products that we have recently received queries about.

Product

Is the item listed in the Drug Tariff?

Is it Does it Can it be in the have a ‘CE’ dispensed blacklist?* mark? on an FP10?

Additional information

Pregnacare tablets

No

No

No

Yes

This item is not listed in Part XVIIIA (the ‘blacklist’) of the Drug Tariff and it is not a medical device.

Zoff adhesive remover wipes

No

No

No

Yes

This item is not a medical device (CE marked) and is not listed in Part XVIIIA (the ‘blacklist’) of the Drug Tariff.

Flexitol Skin Balm

Yes

n/a

Yes

Yes

This item is a medical device (CE marked) and is listed in Part IX of the Drug Tariff.

Respiflo sterile water inhalation solution

No

n/a

Yes

No

This item is a medical device (CE marked) and is not listed in Part IX of the Drug Tariff.

*n/a is because medical devices are not listed in the blacklist.

Please note: If the prescription is an FP10CN or FP10PN (community nurse prescriber), an FP10D (dental prescriber) or an FP10MDA (instalment dispensing), please visit psnc.org.uk/prescriptionforms for more information.

6 Community Pharmacy News – May 2019

LPCS

PSNC’S WORK

FUNDING AND STATISTICS

CONTRACT AND IT

Ask PSNC The PSNC Dispensing and Supply Team provides pharmacy teams with support and advice on a range of topics related to the Drug Tariff and reimbursement. Questions asked in recent months include: Q. I have received a prescription for ’28 x 5mg tablets’; however, there is currently a supply issue with that strength and we can only purchase it above Drug Tariff price. The 2.5mg strength is available and works out at the same Drug Tariff price so can I dispense ’56 x 2.5mg tablets’ instead?

Q. What should I do if I can’t obtain a Part IXA appliance without extra charges?

A. No. Reimbursement will be based on the prescribed strength and quantity (Please note that the ‘PC’ endorsement is not a sufficient endorsement in this situation). If pharmacy teams believe it is in the patient’s best interest to ‘double up’ to support patient care, pharmacy teams are advised to return the prescription to the prescriber so they can make a clinical decision and, if necessary, amend the prescription to ensure correct reimbursement.

A. Products listed in Part IXA and IXR of the Drug Tariff are not eligible for Out Of Pocket (OOP) expense claims.

Q. I have been told by my wholesaler that a Part VIIIA licensed generic product is unavailable. There is no alternative proprietary product available, but a specials manufacturer can prepare this product for me. If I dispense and endorse the unlicensed product will I be reimbursed for it?

A. No. The prescription should be referred back to the prescriber so that they have the opportunity to prescribe an alternative licensed product and/or are aware of the changes in liability caused by an unlicensed product being given to the patient.

If the prescriber believes that the product should be specially manufactured, the prescription should be amended to specify “unlicensed special” within the product description.

If the prescriber has stated the name of the specials manufacturer, NHS Prescription Services will pay based on the endorsed invoice price for the specially manufactured product. Remember that, if an unlicensed product is prescribed, the prescription must be included in the red separator in the monthly submission bundle.

Also, it is helpful to inform the PSNC Dispensing and Supply Team about the shortage. If there is a long-term supply problem, PSNC can make an application to the Department of Health and Social Care to remove the product from the Drug Tariff.

More information on the dispensing of unlicensed medicines is available from psnc.org.uk/specials

In order to list a product in the Drug Tariff, manufacturers must declare that their product “will be readily available to dispensing contractors either through the normal wholesale network or on equivalent terms”. So, if a product is unavailable without additional charges from either the manufacturer or the wholesale network, the manufacturer may not be meeting the requirements for their product to remain listed in the Tariff.

Please report any products in this scenario to the PSNC Dispensing and Supply Team (0203 1220 810 or info@psnc.org.uk) who will investigate and, where necessary, escalate the problem to NHS Prescription Services.

As it can take time to reach a resolution with appliance manufacturers, PSNC recommends considering the following options: • Contact the Part IXA manufacturer to find out whom they supply to and whether it is possible to obtain the product directly without charge.

• Discuss the problem with the prescriber and consider requesting a new prescription for an equivalent product which is available without additional charges.

• As a last resort, NHS pharmacy contractors are not contractually obliged to supply appliances that would not normally be supplied in the course of their business.

Therefore, if a contractor is faced with making a financial loss through dispensing an appliance, they may choose not to dispense it.

Look out for more frequently asked questions next month…

If you would like more information on any of the topics covered, the PSNC Dispensing and Supply Team will be happy to help (0203 1220 810 or email info@psnc.org.uk). psnc.org.uk 7

PSNC’S WORK

FUNDING AND STATISTICS

CONTRACT AND IT

Pharmacy notice board In this section of Community Pharmacy News we have highlighted some key notices for you and your team to be aware of in the coming weeks and months.

Supply issues

e, Merck Sharp & Sinemet tablets: as intermittent supply issues continu of products cturing manufa move Dohme Limited (MSD) has decided to Sinemet some of ance appear the that means to another site. This move p4V50 ug7rj ow.ly/p at: details Full oval. to round from change products will out of stock until Epanutin 50mg Infatabs (phenytoin): Pfizer will be a management plan: with letter a issued been has November 2019. A letter CGRg 6D30o ow.ly/1F

sletterquarterly w e n s Tip uces a Hints & ription Services profdor dispensing

Presc & Tips NHS d ‘Hints er calle tt le s seful w ne some u ontains ctors’. c a ) tr 5 n 3 o c sue ition (Is test ed ice on v The la d a d n ation a en days inform ices’ op n Serv NHS o ti ip r c r o the Pres laims f c , s r a n a ced bin ply Adv and we l ine Sup ic d e nationa M and the Urgent ), S A S (NUM and 3 Service dule 2 f Sche o t u o S. roll gs in EP lled Dru o tr n & Tips o C e Hints s of th n io it d at: d n e u All be fo er can tt spx le 1.a s 19 w 3 e / n k s a .n h s .u b s h .n www

End of antiviral prescribing for influenza

The circulation of influenza in the community has returned to baseline levels so the Department of Health and Social Care has informed prescr ibers and pharmacy teams that antiviral medicines should no longer be prescribe d.

NPA bursary applications now open

cy Association’s Pharmacists can now apply for the National Pharma y. bursar tion Founda ion (NPA) £10,000 Health Educat

who have an interest The annual bursary aims to support pharmacists to community relating ch resear in developing their skills to undertake pharmacy.

Applications close 30th June 2019.

Find out more at: ow.ly/C jRG30o L5bA

8 Community Pharmacy News – May 2019

DISPENSING AND SUPPLY

SERVICES AND COMMISSIONING

THE HEALTHCARE LANDSCAPE

LPCS

What is the Price Change Mechanism?

This factsheet explains how changes to prices are applied to generic and proprietary drugs ordered on NHS prescriptions.

The price of certain drugs may fluctuate from month to month and the ‘Price Change Mechanism’ was introduced to ensure that community pharmacy teams are appropriately reimbursed for the drugs they dispense.

This agreed mechanism was put in place to increase or decrease the reimbursement prices of drugs to catch up with any changes to market prices. The timing of any price change of a drug determines when the change to its reimbursement price comes into effect – which differs depending on whether the drug is a proprietary or generic product.

The difference in timing of changes to reimbursement prices is intended to take into account factors such as assumed stock levels; for example, certain products which are standard fast-moving lines may be readily stocked by most pharmacies.

Why does the Drug Tariff price not always reflect my actual reimbursement price?

The prices published in the monthly Drug Tariff are indicative and may not always reflect the actual reimbursement prices for certain drugs dispensed by contractors for that month. This is because the Drug Tariff is not a live document and as such does not reflect the latest price changes.

The Drug Tariff states: ‘While every effort is made to ensure that each monthly publication of the Drug Tariff includes all amendments made by the Secretary of State and the Welsh Ministers to the price applicable to the relevant period, the need to observe printing deadlines sometimes defeats those efforts. Any omitted amendments will be effective from the date on which they came into force, even if publication of the details is unavoidably delayed.’

The Drug Tariff for the following month is normally prepared by the 15th of the current calendar month and is ready for publication

three working days before the 1st of following month. For example, the June 2019 Drug Tariff would be prepared around 15th May and is ready for publishing by 29th May. Due to time constraints involved in the preparation and publication of the Drug Tariff, the Price Change Mechanism enables the NHS Business Service Authority (NHSBSA) to better manage any price changes for inclusion in the Drug Tariff. Pharmacies are reimbursed at the price notified to NHSBSA (after applying the price change timetable) and not at the Drug Tariff listed-price where there is a difference between the two.

How the Price Change Mechanism works for: Proprietary products For proprietary preparations, including those listed in Part VIIIA products where the price is based on a proprietary product (mainly Category C products*), a price change up to and including the 8th of the month takes effect for prescriptions dispensed in the following month.

A price change after the 8th of the month will be applied for reimbursement purposes to prescriptions dispensed one month later.

Proprietary Products Any change to the list price between the 1st and 8th June would apply to prescriptions dispensed in July

1st June

8th

Any changes to the list price that happen after the 8th June will apply to prescriptions dispensed in August

12th

30th June

For example, if a price change occured on the 12th June, the pharmacy would be reimbursed the new list price in August psnc.org.uk 9

DISPENSING AND SUPPLY

SERVICES AND COMMISSIONING

THE HEALTHCARE LANDSCAPE

For example, if the manufacturer’s list price for a proprietary product changed on 6th June, the new reimbursement price would apply to prescriptions dispensed in July. If a manufacturer’s list price changed on 15th June, the new reimbursement price would apply to prescriptions dispensed in August. *Part VIIIA Category C includes drugs that are not readily available as a generic. The price is based on a particular proprietary product, manufacturer or sometimes supplier Generic products (excluding Category M) For non-proprietary or generic products (mainly Category A* products and excluding those listed as Category M), the reimbursement price change takes place one month earlier than proprietary products. Where price is based on a generic product a price change up to and including the 8th of the month takes effect for prescriptions dispensed in that same month. Any price change after the 8th takes place in the following month.

For example, if the manufacturer’s list price of a Category A drug changed on 6th June, the new reimbursement price would apply to prescriptions submitted for payment with June submission.

However, as the Drug Tariff (including the electronic version) for June would already have been published at the end of May, any price change would only be reflected in the July Drug Tariff.

If a list price for a Category A drug changed on 20th June, the new reimbursement price would apply to prescriptions submitted for payment with July submission. However, the new reimbursement price would be reflected in the August Drug Tariff as it would have missed the cut-off date for entry to the July Drug Tariff. *Part VIIIA Category A are generic drugs which are readily available.

The price for Category A products is based on a weighted average of the list prices from 2 wholesalers and 2 generic manufacturers.

Generic Products (excluding Category M) Any change to the list price between the 1st and 8th June would apply to prescriptions dispensed in June

1st June

8th

Any changes to the list price after the 8th June will apply to prescriptions dispensed in July

12th

30th June

For example, if a price change occured on the 12th June, the pharmacy would be reimbursed at the new list price in July

Category M products Drugs listed as Category M* in the Drug Tariff are not affected by the Price Change Mechanism.

Category M prices are provided by the Department of Health and Social Care (DHSC) each quarter. As DHSC are aware of the price change timetable and the publication deadlines, the prices are received and incorporated in the Drug Tariff prior to the 15th of the month. If contractors are unable to purchase a Category M drug at the Drug Tariff listed price, these should be reported to the PSNC Dispensing and Supply Team using our online feedback form (psnc.org.uk/feedback). PSNC will investigate the extent of the problem and, where necessary apply for a price concession.

10 Community Pharmacy News – May 2019

*Part VIIIA Category M are drugs which are readily available.

More information on Category M price changes is available here: psnc.org.uk/categorym For more information on price concessions, see our page: psnc.org.uk/priceconcessions Non-Drug Tariff lines Price changes for drugs not listed in the Drug Tariff also follow the Price Change Mechanism timeline set out above for both generic and proprietary products.

LPCS

PSNC’S WORK

FUNDING AND STATISTICS

Drug Tariff Watch Below is a quick summary of the changes due to take place from 1st June 2019.

Part VIIIA additions • Alfentanil 5mg/10ml solution for injection ampoules (5) – Rapifen • Alfentanil 5mg/10ml solution for injection ampoules (10) – Hameln Pharmaceuticals Ltd • Budesonide 1mg orodispersible tablets sugar free (90) – Jorveza • Capecitabine 300mg tablets (60) – Accord Healthcare Ltd • Cariprazine 1.5mg capsules (28) – Reagila • Cariprazine 3mg capsules (28) – Reagila • Cariprazine 4.5mg capsules (28) – Reagila • Cariprazine 6mg capsules (28) – Reagila • Chlorhexidine gluconate 1% cream  (250ml) – Hibitane Obstetric • Desmopressin 4micrograms/1ml solution for injection ampoules (10) – DDAVP • Diflucortolone 0.1% cream  (30g) – Nerisone • Diflucortolone 0.1% ointment  (30g) – Nerisone • Diflucortolone 0.3% ointment  (15g) – Nerisone Forte • Fentanyl 100micrograms/dose nasal spray (6 dose (6 x  1)) – Instanyl • Fentanyl 100micrograms/dose nasal spray  (8 dose) – PecFent • Fentanyl 100micrograms/dose nasal spray (32 dose (4 x  8)) – PecFent • Fingolimod 500microgram capsules (28) – Gilenya

• Fluticasone 125micrograms/dose / Formoterol 5micrograms/dose breath actuated inhaler CFC free  (120 dose) – Flutiform K-haler • Fluticasone 50micrograms/dose / Formoterol 5micrograms/dose breath actuated inhaler CFC free V (120 dose) – Flutiform K-haler • *Glycopyrronium bromide 400micrograms/ml oral solution sugar free  (60ml) – Sialanar • Hydrocortisone 1mg granules in capsules for opening (50) – Alkindi • Hydrocortisone 2mg granules in capsules for opening (50) – Alkindi • Hydrocortisone 500microgram granules in capsules for opening (50) – Alkindi • Hydrocortisone 5mg granules in capsules for opening (50) – Alkindi • Ibuprofen 200mg medicated plasters (2) – Nurofen Joint & Muscular Pain Relief • Ibuprofen 200mg medicated plasters (4) – Nurofen Joint & Muscular Pain Relief • Ibuprofen lysine 200mg tablets (8) – Feminax Express • Ibuprofen lysine 200mg tablets (16) – Feminax Express • Ibuprofen lysine 400mg tablets (12) – Nurofen Maximum Strength Migraine Pain • Ibuprofen lysine 400mg tablets (24) – Nurofen Express • Insulin human 100units/ml solution for injection 3.15ml cartridges (5) – Insuman Infusat • Ketamine 500mg/10ml solution for

CONTRACT AND IT

KEY:  Special container * This pack only (others already available) SLS Selected List Scheme

injection vials  (1) – Ketalar • Lidocaine 0.33% / Cetylpyridinium chloride 0.1% oromucosal gel sugar free  (10g) – Calgel • *Magnesium hydroxide 8% oral suspension (500ml) – Alliance Healthcare (Distribution) Ltd • Metronidazole 1g suppositories (10) – Flagyl • Octreotide 500micrograms/1ml solution for injection vials (5) – Pfizer Ltd • Ondansetron 16mg suppositories  (1) – Zofran • Paracetamol 325mg / Isometheptene 65mg capsules (15) – Midrid • Paracetamol 325mg / Isometheptene 65mg capsules (30) – Midrid • Roflumilast 250microgram tablets (28) – Daxas • Solifenacin 1mg/ml oral suspension sugar free (150ml) – Vesicare Part VIIIA deletions • Acemetacin 60mg capsules (90) – Emflex • Hydrocortisone 1% / Pramocaine 1% foam enema (40 dose) – Proctofoam HC • *Magnesium hydroxide 8% oral suspension (200ml) – J M Loveridge Ltd • Methadone 35mg/3.5ml solution for injection ampoules (10) – Physeptone For a full list of the upcoming Drug Tariff changes, including amendments, please visit: ow.ly/KzeO30oN3Ax

Part IX deletions Product

Product Code, Size, Type

BANDAGES - Hero Healthcare Ltd- Carolon - multi-layer compression bandage kit Nélaton Catheter (‘ordinary’ cylindrical Catheter) Single use - Wellspect HealthCare LoFric InstiCath - (Tiemann) Foley Catheter - 2 Way For Long Term Use – Adult - Richardson Healthcare Ltd - Cath-It Advance WOUND MANAGEMENT DRESSINGS - Soft Polymer Wound Contact Dressing with Polyurethane Foam Film Backing - Sterile - Allevyn Gentle TRACHEOSTOMY AND LARYNGECTOMY APPLIANCES - Tracheostomy and Laryngectomy Protectors - Protect (Shower Protector) ILEOSTOMY (DRAINABLE) BAGS - Hollister Ltd - Impression “C” with convex wafer Transparent with beige Comfort backing on body worn side SKIN FILLERS AND PROTECTIVES – Respond Healthcare Ltd - OstoMart Astoa Barrier Cream

All sizes 10ch (821000) and 14ch (821400) 10ml, 12-16ch (908112-16) All sizes

71-0070-00 22mm (3281) 100g (ABC100) and sachets 2g (ABC2 30)

psnc.org.uk 11

PSNC’S WORK

FUNDING AND STATISTICS

CONTRACT AND IT

PSNC resources library In this section of Community Pharmacy News we have provided details of some of the resources that PSNC has produced this month.

PSNC Briefings PSNC Briefing 013/19: An introduction to Primary Care Networks This briefing provides an explanation for community pharmacy teams of what Primary Care Networks (PCNs) are and their role in the NHS. LPCs may wish to use it as part of local work to engage contractors in the networks.

Download from: ow.ly/3ndn30oJXwd PSNC Briefing 015/19: Supporting community pharmacies to engage with PCNs – potential actions for LPCs A list of suggested actions which LPCs can take to ensure community pharmacy is effectively engaged in the work of Primary Care Networks (PCNs) and contractors are supported to play their part in this.

Download from: ow.ly/6dzb30oJXwB PSNC Briefing 016/19: EPS Controlled Drugs FAQs This briefing aims to assist community pharmacy teams in dispensing Controlled Drugs (CDs) via the Electronic Prescription Service (EPS) by answering a number of common queries received by PSNC on this issue.

Download from: ow.ly/azBH30oJXyR See all our PSNC Briefings in our database at: psnc.org.uk/briefings

Other resources PCNs and community pharmacy video Zainab Al-Kharsan, Service Development Pharmacist at PSNC, has recorded a short presentation on Primary Care Networks (PCNs) and what their introduction will mean for community pharmacy.

Watch now: psnc.org.uk/pcnresources Look out for additional resources as you explore our website: psnc.org.uk

Email news alerts Children’s oral health campaign – contractual requirement (29th April) Making community pharmacies aware of their mandatory participation in NHS England children’s oral health campaign, running between 13th May and 13th June 2019.

Read now: ow.ly/2SsX30oJYPZ Future of pharmacy animation is launched (30th April) Announcement of PSNC’s video animation explaining how community pharmacies are likely to fit into the NHS of the future and how the sector must start planning for those changes now.

Read now: ow.ly/6sl130oJYQK Not receiving our emails? Sign up now at: psnc.org.uk/enews

PSNC website For up to date information and news on community pharmacy issues, visit the PSNC website at psnc.org.uk PSNC Community Pharmacy News is published by: The Pharmaceutical Services Negotiating Committee, 14 Hosier Lane, London, EC1A 9LQ Community Pharmacy News is edited by: Melinda Mabbutt who can be contacted at the above address or by email at: mmabbutt@psnc.org.uk PSNC Office: 0203 122 0810

© PSNC